As per our report, the global early toxicity testing market size was worth USD 829.2 million in 2020. This figure is forecasted to be growing at a CAGR of 7.88% and will reach USD 1211.5 million by 2025.
Toxicity is the degree of the menace posed by a substance to the living organism. The effects of chemical substance on the existing body are studied to select a possible drug candidate during the development of the newer molecule. The toxicity testing carried out to decide the amount and type of drug such as alcohol, cocaine, amphetamine, barbiturates, benzodiazepine present in the blood cell. Poisonous quality is good explanations behind the disappointment of medication development and dismissal of medication advancement. It is a result of measurements, half-life and different measurement of medication.
MARKET DRIVERS
Growing demand for early toxicity testing and technological developments in the R & D are primarily escalating market growth.
The global toxicity testing market is anticipated to have the highest growth in the coming year. Rise in the R&D activities and increase in strict government authority in public healthcare welfare are likely to bolster the demand of the market. Advanced technologies in in-vitro technique, increase in adoption of the in-vitro model and gaining of early toxicity testing in the several industries propel the market growth. Toxicity studies are studied to an expert level from CROs to pace up the process and increase in attention toward early detection of toxicity is anticipated to drive the global early toxicity testing market in future.
MARKET RESTRAINTS
Limited awareness about the application of early toxicity testing and limitation of preclinical testing are restraining market growth. Stringent government rules and side effects are hampering the demand for early toxicity testing market.
RECENT MARKET DEVELOPMENTS
In February 2018, Charles River Laboratories Inc., an American company specializing in the preclinical and clinical laboratory-acquired MPI research with the transaction of USD 800 million.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 – 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 - 2025 |
|
Segments Covered |
By Technique, Assays, End User, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This market research report on the global early toxicity testing market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2025.
Early Toxicity Testing Market Analysis - By Technique:
Based on the technique, the in-vitro segment was the leader in 2019. This segment held for a market share of 70.0% in the last year and is estimated to remain its supremacy over the period. It is due to system circulation, where it is the most preferred method in drug distribution.
In-Silico segment is expected to have the fastest-growing segment over the period following in-vitro segment. The growth is attributed due to an increase in the obtainment of the benefits provided by the technique. Another factor fueling the In-Silico segment is the adoption of computer-based techniques in the diagnostic centres and laboratories.
Early Toxicity Testing Market Analysis - By Assays:
Based on the Assays analysis, cell-based Elisa is estimated to lead the market during the analysis period. These assays do not mandatorily eliminate clinical trials but rather support human experimentation less of a gamble.
Early Toxicity Testing Market Analysis - By End User:
Based on the end-user, the pharmaceutical segment will show strong growth during the forecast period. The growth is associated with factors such as increase fondness for in-vitro testing in this pharmaceuticals industry.
The cosmetic segment is considered to have the fastest growth over the analysis period. The increase is due to factors like growing aesthetic consciousness, increasing disposable income across the globe, new product launches in the field of cosmetic and strict government guidelines to monitor the nature of chemicals used in the products.
Early Toxicity Testing Market Analysis - By Region:
Regionally, the North American region is expected to have the most significant revenue, followed by Europe during the forecast period. The growth in this region attributed to the rise in the healthcare infrastructure, favourable government funds in the healthcare sector and the presence of large pharmaceutical companies in this region.
Europe is expected to have a robust growth rate from 2019 to 2024. Germany is the leading nation of the European region. The growth of this region is based on factors like increasing awareness and favourable policies from the government.
However, Asia-Pacific is expected to have the highest CAGR in the coming years owing to the rise in disposable income and growing demographics. The growth is due to rising efforts for new pharmaceuticals molecules and acquisition of new technologies to make better quality products. Countries like China and India are majorly contributing to the market growth. Also, growing research and development of toxic tests to develop new cell assays methods is enhancing the demand of the market.
Latin America is expected to have steady growth during the period. The growth of this region is caused due to increasing awareness of regulatory authorities and advance technologies accelerating market growth.
The Middle East & Africa region is expected to have a slow growth over the early toxicity testing market over the period. Rising demand for better treatment procedures is to fuel market growth.
TOP COMPANIES IN THE MARKET
List of key market participants in the global early toxicity testing market profiled in this report are Covance, Thermo Fisher Scientific, Quest Diagnostics Corporation, Agilent Technologies, Sigma Aldrich, BD Biosciences, Bio-Rad, Gene Logic, Accelrys and Charles River Laboratories.
Related Reports
